SCM
Sio Capital Management Portfolio holdings
AUM
$604M
Turnover
53.26%
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
-1.39%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$402M
AUM Growth
-$90.4M
(-18%)
Cap. Flow
-$94.9M
Cap. Flow
% of AUM
-23.6%
Top 10 Holdings %
Top 10 Hldgs %
43.57%
Holding
105
New
16
Increased
19
Reduced
23
Closed
32
Avg Time Held Equity + Options
0.8
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.5
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aveanna Healthcare
AVAH
|
+$14.3M |
| 2 |
Amgen
AMGN
|
+$8.61M |
| 3 |
Integer Holdings
ITGR
|
+$6.16M |
| 4 |
HealthEquity
HQY
|
+$4.95M |
| 5 |
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
+$4.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cardinal Health
CAH
|
+$14.1M |
| 2 |
Curis
CRIS
|
+$11.5M |
| 3 |
Merck
MRK
|
+$9.64M |
| 4 |
Icon
ICLR
|
+$9.33M |
| 5 |
GSK
GSK
|
+$9.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.07% |
| 2 | Miscellaneous | 14.4% |
| 3 | Consumer Staples | 2.03% |
| 4 | Technology | 0.88% |
| 5 | Industrials | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
Ascendis Pharma A/S
ASND
$14.9B
| $33.1M | 8.24% |
+251,900
| New | +$33.6M |
2021 Q2
0 quarters
|
|
|
2
Curis
CRIS
$1.45M
| $27.2M | 6.75% |
8,411
-2,543
| -23% | -$11.5M |
2020 Q2
4 quarters
|
|
3
Cigna
CI
$76.5B
| $20.7M | 5.14% |
87,192
-19,773
| -18% | -$4.94M |
2020 Q3
3 quarters
|
|
|
SOLY
4
DELISTED
Soliton, Inc.
SOLY
| $18.6M | 4.61% |
824,803
| – | – |
2020 Q2
4 quarters
|
|
5
SPDR Gold Trust
GLD
$139B
| $15.8M | 3.93% |
95,430
-1,579
| -2% | -$268K |
2020 Q1
5 quarters
|
|
|
6
Aveanna Healthcare
AVAH
$2.7B
| $14.9M | 3.7% |
+1,201,607
| New | +$14.3M |
2021 Q2
0 quarters
|
|
7
HCA Healthcare
HCA
$102B
| $13.6M | 3.37% |
65,573
-7,600
| -10% | -$1.55M |
2018 Q1
13 quarters
|
|
8
Centene
CNC
$34.7B
| $11.3M | 2.82% |
155,616
-61,884
| -28% | -$4.24M |
2021 Q1
1 quarter
|
|
9
Universal Health Services
UHS
$11B
| $10.7M | 2.66% |
73,135
+5,000
| +7% | +$756K |
2020 Q4
2 quarters
|
|
10
McKesson
MCK
$114B
| $9.49M | 2.36% |
49,624
+10,731
| +28% | +$2.07M |
2019 Q3
7 quarters
|
|
|
ALBO
11
DELISTED
Albireo Pharma Inc
ALBO
| $9.34M | 2.32% |
265,616
-2,730
| -1% | -$88.8K |
2020 Q3
3 quarters
|
|
|
HRC
12
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $8.71M | 2.16% |
76,647
-31,000
| -29% | -$3.47M |
2020 Q2
4 quarters
|
|
|
13
Amgen
AMGN
$230B
| $8.53M | 2.12% |
+35,000
| New | +$8.61M |
2021 Q2
0 quarters
|
|
14
United Therapeutics
UTHR
$23.2B
| $8.38M | 2.08% |
46,712
-9,332
| -17% | -$1.78M |
2018 Q4
10 quarters
|
|
15
Herbalife
HLF
$1.49B
| $8.16M | 2.03% |
154,838
+6,119
| +4% | +$304K |
2020 Q3
3 quarters
|
|
16
Mirum Pharmaceuticals
MIRM
$5.19B
| $7.87M | 1.96% |
454,892
+17,754
| +4% | +$318K |
2020 Q4
2 quarters
|
|
17
Spruce Biosciences
SPRB
$112M
| $7.26M | 1.8% |
8,630
-2,208
| -20% | -$2.36M |
2020 Q4
2 quarters
|
|
|
HZNP
18
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.32M | 1.57% |
67,471
+2,670
| +4% | +$246K |
2020 Q3
3 quarters
|
|
|
19
Integer Holdings
ITGR
$4.3B
| $6.29M | 1.56% |
+66,828
| New | +$6.16M |
2021 Q2
0 quarters
|
|
20
DELISTED
Affimed
AFMD
| $6.07M | 1.51% |
71,458
+16,654
| +30% | +$1.52M |
2021 Q1
1 quarter
|
|
21
Coherus Oncology
CHRS
$162M
| $5.72M | 1.42% |
413,733
-434,129
| -51% | -$6.15M |
2019 Q2
8 quarters
|
|
|
SYNH
22
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $5.6M | 1.39% |
62,598
+2,573
| +4% | +$217K |
2020 Q3
3 quarters
|
|
|
AYLA
23
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
| $5.53M | 1.38% |
542,977
+52,989
| +11% | +$544K |
2020 Q2
4 quarters
|
|
24
X4 Pharmaceuticals
XFOR
$243M
| $5.23M | 1.3% |
26,820
| – | – |
2021 Q1
1 quarter
|
|
|
25
HealthEquity
HQY
$7.43B
| $5.23M | 1.3% |
+64,958
| New | +$4.95M |
2021 Q2
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, Sio Capital Management held 105 positions worth $402M, down 18% from $493M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Sio Capital Management withdrew a net $94.9M in Q2 2021, closing 32 positions and reducing 23 holdings. Its most notable exit was Merck, an estimated $9.64M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 91% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Sio Capital Management opened a new position in Aveanna Healthcare worth $14.9M.
- Sio Capital Management's largest Q2 2021 buy was Aveanna Healthcare: 1,201,607 shares worth $14.9M.
- Sio Capital Management added most to NeuBase Therapeutics, Inc. Common Stock in Q2 2021, an estimated $2.62M increase.
- Sio Capital Management's biggest Q2 2021 reduction was Cardinal Health, cutting an estimated $14.1M.
- Sio Capital Management fully exited Merck in Q2 2021, selling an estimated $9.64M.
- Sio Capital Management's ten largest holdings make up 44% of its $402M portfolio in Q2 2021.
- Sio Capital Management opened 16 new positions and closed 32 in Q2 2021.
- Sio Capital Management's portfolio value fell 18% quarter-over-quarter to $402M.
Based on Sio Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.